InvestSMART

Invion Limited (ASX:IVX)

ALERT: Price-sensitive ASX Announcement for IVX
Current share price for IVX : $0.035 -0.046 (-56.79%)+
Announcement
Release
27 Feb 2026 9:32AM
Price at Release
$0.081
Full Release
download
Summary
Invion Limited's Appendix 4D and Half Year Financial Report for the period ending 31 December 2025 outlines a significant loss of $3,565,836 for the half-year, compared to a loss of $1,872,230 in the previous period. The report highlights movements in equity, including an increase in issued capital due to options and share-based payments. The financial position at the end of the period shows total assets of $8,088,461 and net assets of $5,706,180, reflecting decreased cash reserves and the issuance of convertible notes to support ongoing activities. The company did not pay or declare any dividends during this period and secured additional funding through a convertible note offering and a R&D tax incentive loan facility. This financial situation suggests an operational focus on research and development, particularly involving the PhotosoftTM technology, aimed at addressing unmet medical needs with potential financial incentives and market advantages.
Key Points
  • Loss after income tax for the half-year: $3,565,836
  • Total assets as of 31 December 2025: $8,088,461
  • Net assets as of 31 December 2025: $5,706,180
  • No dividends paid or declared during the period
  • Convertible notes issued for additional funding
  • Significant expenditure on research and development
  • PhotosoftTM technology focus and potential Orphan Drug Designation
  • R&D tax incentive loan facility secured
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.